Folexin AI Market Strategy Report - Hair Loss Treatments

Answer Capsule

Folexin registers near-zero recommendation power across all major AI platforms in the Hair Loss Treatments category for June 2026. The brand appears in 24 out of 1,102 observations but receives only one valid recommendation across all platforms and clusters. Folexin holds a net sentiment score of 0.0, meaning its mentions are overwhelmingly neutral with no positive framing driving commercial outcomes. The clearest win is a narrow Gemini signal where the brand's single valid recommendation lands at an average rank of 2.0. The clearest opportunity is building a citation architecture that supports recommendation-stage visibility, as Folexin currently has presence without commercial impact.

Who This Report Is For

This report is for Folexin marketing, product, and executive teams evaluating the brand's current AI recommendation visibility and competitive position in the hair loss treatment category.

Report Card

• Report type: AI Company Market Strategy Report
• Target company: Folexin
• Category / market studied: Hair Loss Treatments
• Reporting month: June 2026
• AI platforms tracked: ChatGPT, Copilot, Gemini, Google AI Mode, Google AI Overviews, Perplexity
• Public high-intent clusters: 3 (Best Telehealth & Online Prescription Services, Telehealth Platform Comparisons, Telehealth & Online Prescription Pricing)
• AI observations analyzed: 1,102
• Competitors tracked: Nutrafol, Rogaine, Keeps, Hims, Happy Head, Bosley, HairClub, Ro (Roman), Propecia (Merck)

Executive Summary

Folexin has a raw mention presence rate of 2.2% across 1,102 observations, appearing in 24 AI responses. Of those 24 appearances, 22 are neutral, 1 is negative, and 1 is positive. The brand receives exactly one valid recommendation across all platforms and clusters, yielding a valid recommendation coverage of 0.09%. Its monthly AI Authority Value is $16,996, representing 0.03% of the total $53.2 million monthly AI opportunity in the category.

The strongest cluster for Folexin is Telehealth Platform Comparisons (C02), where the brand appears in 5 observations and receives its only valid recommendation. The weakest cluster is Telehealth & Online Prescription Pricing (C03), where Folexin appears in just 1 observation with no recommendation credit. On a platform level, Gemini provides the strongest signal with 10 appearances and the brand's only valid recommendation. ChatGPT shows zero presence in the public packet. Google AI Overviews and Perplexity each show minimal presence with no recommendation credit.

Folexin's position is commercially fragile. The brand is not being ignored by AI systems outright, but it is being retrieved and then passed over. This pattern of neutral visibility without recommendation conversion means Folexin surfaces in AI responses while failing to be advanced as a treatment option for consumers making active purchase decisions. The gap between presence and recommendation credit is the defining problem the data reveals.

The distance between Folexin and the category leader is substantial. Nutrafol appears in 522 observations with 274 valid recommendations and a monthly AI Authority Value of $3.9 million. Folexin appears in 24 observations with 1 valid recommendation and a monthly AI Authority Value of $16,996. Competitor displacement in this category is not marginal. It is structural.

What Folexin Is Winning

Folexin has one narrow but meaningful pocket of visibility on Gemini. The platform accounts for 10 of the brand's 24 total appearances and delivers its only valid recommendation across all platforms and clusters. When that recommendation is granted, Folexin lands at an average rank of 2.0, a competitive position relative to the size of the brand's overall footprint. Gemini also accounts for $15,397 of Folexin's $16,996 total AI Authority Value, confirming it as the only platform with commercial signal.

The brand also carries a net sentiment score of 0.0, which is not a strength in isolation but is a cleaner baseline than a brand with negative framing would have. Folexin is not being framed as a cautionary option or a competitor anchor. Its mentions are predominantly neutral references. This means the remediation task begins with building recommendation signal rather than reversing reputational damage, which is a more tractable starting position.

Where Folexin Has the Clearest AI Visibility Gaps

Folexin has zero valid recommendations in the Best Telehealth & Online Prescription Services cluster (C01) and the Telehealth & Online Prescription Pricing cluster (C03). In C01, the brand appears in 18 observations but receives no recommendation credit. In C03, it appears in just 1 observation with no recommendation credit. Both clusters represent high-intent buying moments where consumers are actively evaluating treatment options. Folexin is present in these moments but not being chosen.

The platform gap is equally significant. Folexin has no presence on ChatGPT in the public dataset. On Copilot, the brand appears in 2 observations, both with neutral or negative framing and no positive recommendation. On Google AI Mode, Folexin appears in 9 observations, all neutral, with no recommendation credit. On Google AI Overviews and Perplexity, the brand registers 1 and 2 appearances respectively, each without recommendation credit. Across five of the six tracked platforms, Folexin has no valid recommendations at all.

The competitive displacement pattern is consistent. Nutrafol, Rogaine, and Keeps are capturing the shortlist positions Folexin does not reach. The brand's current public evidence layer is not generating the signal AI systems use to advance a treatment option from mention to recommendation. The data does not identify exactly which source or framing gaps are responsible, but the conversion rate from mention to recommendation (1 of 24 appearances, or 4.2%) is low enough to confirm the pattern is structural rather than incidental.

Biggest Opportunity

The single biggest opportunity for Folexin is converting its existing Gemini visibility into consistent recommendation coverage by strengthening the citation and evidence architecture that Gemini can retrieve during high-intent queries. Gemini is the only platform where the brand has received recommendation credit. It is also the platform where Folexin's neutral mentions are closest to converting into positive framing. If Folexin builds structured comparison content, clinical evidence, and editorial source material that Gemini can surface in response to treatment evaluation and platform comparison queries, the brand's recommendation rate on that platform may improve from its current baseline of 1 recommendation in 10 appearances. This is not a broad-market strategy. It is a targeted first move that the data supports.

Prompt Evidence

Gemini / Telehealth Platform Comparisons Prompt: "Telehealth Platform Comparisons" Result: Folexin appeared in 5 observations and received 1 valid recommendation with an average rank of 2.0.

Gemini / Best Telehealth & Online Prescription Services Prompt: "Best Telehealth & Online Prescription Services" Result: Folexin appeared in 10 observations with all mentions classified as neutral and no valid recommendation credit awarded.

Copilot / Telehealth Platform Comparisons Prompt: "Telehealth Platform Comparisons" Result: Folexin appeared in 2 observations, with 1 negative mention and 1 neutral mention, and received no recommendation credit on either.

Google AI Mode / Best Telehealth & Online Prescription Services Prompt: "Best Telehealth & Online Prescription Services" Result: Folexin appeared in 9 observations, all classified as neutral, with no recommendation credit awarded across any appearance.

What CiteWorks Studio Would Do Next

Phase 1: AI Market Discovery Audit Complete a full 10-cluster audit to identify which specific prompts and platforms offer the highest potential for recommendation conversion given Folexin's current mention-to-recommendation gap.

Phase 2: Recommendation Readiness Plan Assess Folexin's current public evidence layer to determine why AI systems retrieve the brand in 24 observations but advance it to recommendation in only 1.

Phase 3: Owned Answer Layer Buildout Develop structured content that addresses comparison, pricing, and treatment efficacy queries where Folexin is currently present without recommendation credit, with priority on Gemini-facing source material.

Phase 4: Citation / Authority Layer Development Build clinical, editorial, and comparison source material that AI systems can retrieve and cite when evaluating hair loss treatment options, targeting the C01 and C02 clusters where Folexin has existing visibility but no recommendation conversion.

Phase 5: Monthly AI Visibility and Recommendation Tracking Monitor Folexin's recommendation coverage, rank position, and sentiment across all six tracked platforms to measure movement against both the current baseline and the category leaders.

Why This Matters

Folexin is currently visible in AI responses but commercially invisible within them. The brand appears in 24 observations but receives only 1 valid recommendation. AI systems are retrieving Folexin and then selecting other brands to shortlist. For a brand operating in a category where Nutrafol, Rogaine, and Keeps collectively capture the dominant share of recommendation value, the gap between presence and recommendation power is not a minor positioning problem. It is the central commercial risk the data identifies.

The next move for Folexin is not to pursue more mentions. It is to understand why AI systems retrieve the brand and then pass it over, and to build the citation architecture that supports recommendation-stage visibility. Raw presence without recommendation conversion produces no buyer shortlist eligibility. Without a targeted correction of the prompt, page, and citation layers, Folexin will continue to appear in AI responses without capturing the moments where buying decisions are being shaped.

Core Metrics

• Mentions: 24
• Valid recommendations: 1
• Top 3 recommendation count: 1
• Rank 1 recommendation count: 0
• Average recommended rank: 2.0
• Positive mentions: 1
• Neutral mentions: 22
• Negative mentions: 1
• Raw mention presence rate: 2.2%
• Valid recommendation coverage: 0.09%
• Top 3 recommendation rate: 0.09%
• Rank 1 recommendation rate: 0.0%
• Strongest cluster by recommendation behavior: Telehealth Platform Comparisons (C02)
• Strongest platform by recommendation behavior: Gemini

Sentiment Score

Sentiment Score = (positive mentions x 1 + neutral mentions x 0 + negative mentions x -1) / total mentions

Folexin: (1 x 1 + 22 x 0 + 1 x -1) / 24 = 0 / 24 = 0.0

A sentiment score of 0.0 means Folexin's AI mentions are directionally neutral. The brand is being referenced without positive or negative framing across the vast majority of its appearances. This distinction matters because unclassified mention counts are misleading on their own. A positive recommendation, a neutral reference, a cautionary mention, and a competitor-displaced mention carry entirely different commercial weight. Counting all of them as equivalent visibility wins produces a false picture of AI market position. Classified sentiment is required before any AI visibility metric is interpreted as a business signal. For Folexin, the neutral framing confirms the brand is present in AI responses but is not being endorsed, which means the remediation task is building recommendation signal from a neutral baseline rather than repairing negative framing.

Sentiment by Platform

Methodology

1. This analysis is based on the LLM Authority Index benchmark for the Hair Loss Treatments category, published for June 2026.
2. The reporting window covers June 2026. This is a point-in-time benchmark and does not reflect ongoing model or output changes that may occur after the reporting date.
3. Six AI platforms were tracked: ChatGPT, Copilot, Gemini, Google AI Mode, Google AI Overviews, and Perplexity.
4. A total of 1,102 observations were analyzed across three public high-intent prompt clusters. The unique prompt count within those observations is not available in the public version of the benchmark.
5. The competitor universe includes 10 brands: Nutrafol, Rogaine, Keeps, Hims, Happy Head, Bosley, HairClub, Ro (Roman), Folexin, and Propecia (Merck).
6. Three public clusters are reported: Best Telehealth & Online Prescription Services (C01, consideration stage), Telehealth Platform Comparisons (C02, evaluation stage), and Telehealth & Online Prescription Pricing (C03, decision stage). The full LLM Authority Index report for this category includes 10 clusters. Metrics reported here reflect only the 3 public clusters.
7. Stage 0 refers to the raw observation collection and extraction phase conducted before metrics are calculated. Stage 0 data informs mention classification, sentiment tagging, and recommendation credit assignment.
8. A mention is defined as any appearance of the brand name in an AI-generated response, regardless of sentiment, rank, or recommendation status. Mentions are not equivalent to recommendations.
9. A valid recommendation is a positive, shortlist-quality recommendation or ranked recommendation that earns recommendation credit in the LLM Authority Index scoring model. Neutral references, cautionary mentions, and competitor-displaced appearances do not qualify as valid recommendations.
10. The AI Authority Value is a modeled metric combining recommendation value and visibility assist value. It is a directional estimate and does not represent revenue, pipeline, or booked demand.
11. Limitations: AI outputs can change as models update and source material shifts. This report covers 3 of 10 tracked clusters and does not represent a full market census. Modeled values are estimates and not revenue figures. Ahrefs search and source data, if available, would serve only as supporting evidence for the traditional organic and backlink layer and would not override AI recommendation metrics.

See How AI Is Recommending Your Brand

The public benchmark shows the market shape. A company-specific analysis maps which prompts Folexin wins or loses, which AI platforms are under-recognizing the brand, which source layers are shaping current recommendations, and what changes may improve AI shortlist eligibility across the full 10-cluster dataset. Contact CiteWorks Studio to begin an AI Visibility Audit for Folexin.